FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296430> ?p ?o ?g. }

• W4367296430 abstract "<h3>Objective:</h3> Compare the efficacy and safety of zavegepant nasal spray with placebo in the acute treatment of migraine. <h3>Background:</h3> Zavegepant is the only small molecule CGRP receptor antagonist delivered by nasal spray in late-stage development for the acute treatment of migraine. In a Phase 1 study with healthy subjects, the 10 mg nasal spray was rapidly absorbed (T_max ~30 minutes). In a dose-ranging study (NCT03872453), zavegepant 10 mg was the optimal dose. <h3>Design/Methods:</h3> In this phase 3, double-blind, randomized, placebo-controlled trial (NCT04571060), adults with a history of 2–8 moderate or severe monthly migraine attacks self-administered 1 dose of zavegepant 10 mg nasal spray or placebo to treat 1 migraine attack of moderate or severe pain intensity. The coprimary efficacy endpoints were freedom from pain and freedom from the most bothersome symptom (MBS) at 2 hours postdose. <h3>Results:</h3> Of 1405 randomized subjects, 1269 (mean age 41 years, 83% female) were evaluable for efficacy (zavegepant n=623, placebo n=646). Zavegepant was superior to placebo for pain freedom (23.6% vs 14.9%, <i>p</i><0.0001) and freedom from the MBS (39.6% vs 31.1%, <i>p</i>=0.0012) at 2 hours postdose. Secondary endpoints included pain relief at 15 minutes (15.9% vs 8.0%, <i>p</i><0.0001) and 2 hours (58.7% vs 49.7%, <i>p</i>=0.0012); return to normal function at 30 minutes (10.5% vs 6.1%, <i>p</i>=0.0059) and 2 hours (35.8% vs 25.6%, <i>p</i>=0.0001); and sustained pain relief 2 to 48 hours (36.1% vs 29.6%, <i>p</i>=0.013) postdose. The most common (≥2%) adverse events (zavegepant vs placebo) were dysgeusia (20.5% vs 4.7%), nasal discomfort (3.7% vs .8%), and nausea (3.2% vs 1.1%). Most adverse events were mild or moderate; none were serious. <h3>Conclusions:</h3> Zavegepant nasal spray was effective for the acute treatment of migraine, achieving its coprimary endpoints and providing onset of pain relief as early as 15 minutes postdose, sustained benefits to 48 hours postdose, and favorable safety and tolerability. <b>Disclosure:</b> Dr. Mullin has received personal compensation in the range of $0-$499 for serving as a Consultant for Vorso. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mullin has received personal compensation in the range of $0-$499 for serving as a Consultant for Theranica. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Croop has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Croop has stock in Biohaven Pharmaceutical Holding Co Ltd. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care. Dr. Pavlovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Mrs. Mosher has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Mrs. Mosher has stock in Biohaven Pharmaceuticals. The institution of Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Nocira. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vorso/Nesos. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alder/Lundbeck. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. The institution of Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. Smith has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurolief. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nocira. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. The institution of Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie/Allergan. The institution of Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. The institution of Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Dr. Smith has stock in United Health Group. The institution of Dr. Smith has received research support from Aeon. The institution of Dr. Smith has received research support from Alder/Lundbeck. The institution of Dr. Smith has received research support from Alnylam. The institution of Dr. Smith has received research support from Amgen. The institution of Dr. Smith has received research support from Abbvie/Allergan. The institution of Dr. Smith has received research support from Biohaven. The institution of an immediate family member of Dr. Smith has received research support from Eliem Pharmaceuticals. The institution of Dr. Smith has received research support from Lilly. The institution of Dr. Smith has received research support from Pfizer. The institution of Dr. Smith has received research support from Nocira. The institution of Dr. Smith has received research support from Novo Nordisk. The institution of Dr. Smith has received research support from Teva. The institution of Dr. Smith has received research support from Theranica. The institution of Dr. Smith has received research support from Vorso/Nesos. Dr. Smith has a non-compensated relationship as a Board Member with National Headache Foundation that is relevant to AAN interests or activities. Jennifer Madonia has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Jennifer Madonia has stock in Biohaven Pharmaceuticals. Meghan Lovegren has received personal compensation for serving as an employee of Biohaven Pharmaceutials, Inc.. Meghan Lovegren has stock in Biohaven Pharmaceuticals, Inc.. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NINDS. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from Veterans Administration. The institution of Dr. Lipton has received research support from NIH. Dr. Lipton has received publishing royalties from a publication relating to health care." @default.
• W4367296430 created "2023-04-29" @default.
• W4367296430 creator A5018036182 @default.
• W4367296430 creator A5027192633 @default.
• W4367296430 creator A5029703470 @default.
• W4367296430 creator A5032171459 @default.
• W4367296430 creator A5054020423 @default.
• W4367296430 creator A5054082461 @default.
• W4367296430 creator A5060859207 @default.
• W4367296430 creator A5086458638 @default.
• W4367296430 date "2023-04-25" @default.
• W4367296430 modified "2023-10-17" @default.
• W4367296430 title "Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial (PL5.002)" @default.
• W4367296430 doi "https://doi.org/10.1212/wnl.0000000000202039" @default.
• W4367296430 hasPublicationYear "2023" @default.
• W4367296430 type Work @default.
• W4367296430 citedByCount "0" @default.
• W4367296430 crossrefType "proceedings-article" @default.
• W4367296430 hasAuthorship W4367296430A5018036182 @default.
• W4367296430 hasAuthorship W4367296430A5027192633 @default.
• W4367296430 hasAuthorship W4367296430A5029703470 @default.
• W4367296430 hasAuthorship W4367296430A5032171459 @default.
• W4367296430 hasAuthorship W4367296430A5054020423 @default.
• W4367296430 hasAuthorship W4367296430A5054082461 @default.
• W4367296430 hasAuthorship W4367296430A5060859207 @default.
• W4367296430 hasAuthorship W4367296430A5086458638 @default.
• W4367296430 hasConcept C142724271 @default.
• W4367296430 hasConcept C204787440 @default.
• W4367296430 hasConcept C27081682 @default.
• W4367296430 hasConcept C2778541695 @default.
• W4367296430 hasConcept C2780973058 @default.
• W4367296430 hasConcept C2991744798 @default.
• W4367296430 hasConcept C3017807917 @default.
• W4367296430 hasConcept C42219234 @default.
• W4367296430 hasConcept C71924100 @default.
• W4367296430 hasConcept C85663871 @default.
• W4367296430 hasConcept C98274493 @default.
• W4367296430 hasConceptScore W4367296430C142724271 @default.
• W4367296430 hasConceptScore W4367296430C204787440 @default.
• W4367296430 hasConceptScore W4367296430C27081682 @default.
• W4367296430 hasConceptScore W4367296430C2778541695 @default.
• W4367296430 hasConceptScore W4367296430C2780973058 @default.
• W4367296430 hasConceptScore W4367296430C2991744798 @default.
• W4367296430 hasConceptScore W4367296430C3017807917 @default.
• W4367296430 hasConceptScore W4367296430C42219234 @default.
• W4367296430 hasConceptScore W4367296430C71924100 @default.
• W4367296430 hasConceptScore W4367296430C85663871 @default.
• W4367296430 hasConceptScore W4367296430C98274493 @default.
• W4367296430 hasLocation W43672964301 @default.
• W4367296430 hasOpenAccess W4367296430 @default.
• W4367296430 hasPrimaryLocation W43672964301 @default.
• W4367296430 hasRelatedWork W195323158 @default.
• W4367296430 hasRelatedWork W1990151540 @default.
• W4367296430 hasRelatedWork W1992517622 @default.
• W4367296430 hasRelatedWork W2023657958 @default.
• W4367296430 hasRelatedWork W2032572675 @default.
• W4367296430 hasRelatedWork W2117301193 @default.
• W4367296430 hasRelatedWork W2133689532 @default.
• W4367296430 hasRelatedWork W2410435295 @default.
• W4367296430 hasRelatedWork W2753271370 @default.
• W4367296430 hasRelatedWork W4256475059 @default.
• W4367296430 isParatext "false" @default.
• W4367296430 isRetracted "false" @default.
• W4367296430 workType "article" @default.